Zepbound for Sleep Apnea: Off-Label Use, Evidence, and Monitoring

What Zepbound Is Approved For (and What It Is Not)

Zepbound (tirzepatide) received FDA approval in November 2023 strictly for chronic weight management. The approved population includes adults with a body mass index (BMI) of 30 kg/m² or greater, or 27 kg/m² or greater with at least one weight-related condition such as hypertension, type 2 diabetes, or dyslipidemia. It is not approved for obstructive sleep apnea.

That distinction matters. Off-label prescribing is legal and common in U.S. medicine, but it shifts the evidence burden onto the prescribing clinician. The Endocrine Society's 2024 clinical practice guideline on pharmacotherapy for obesity acknowledges tirzepatide's weight-loss efficacy but does not list OSA as a standalone indication. When a clinician writes tirzepatide for a patient whose primary complaint is sleep apnea, they are making a clinical judgment that the weight-loss mechanism will secondarily improve the airway pathology. That judgment has growing support from trial data, but it is not yet backed by an FDA-labeled indication or guideline endorsement specific to OSA.

Tirzepatide is a dual GIP/GLP-1 receptor agonist administered as a once-weekly subcutaneous injection. Doses start at 2.5 mg and titrate upward every four weeks to 5 mg, 7.5 mg, 10 mg, 12.5 mg, or a maximum of 15 mg, depending on tolerability and response [1].

The Link Between Obesity and Obstructive Sleep Apnea

Obstructive sleep apnea affects an estimated 936 million adults worldwide according to a 2019 Lancet Respiratory Medicine analysis, and obesity is its single strongest modifiable risk factor [2]. Fat deposits in the parapharyngeal space narrow the upper airway. Increased abdominal adiposity reduces lung volumes, which lowers caudal traction on the trachea and makes the pharynx more collapsible during sleep.

The Wisconsin Sleep Cohort Study found that a 10% weight gain predicted a 32% increase in AHI and a six-fold increase in the odds of developing moderate-to-severe OSA over a four-year period [3]. The relationship also works in reverse. A meta-analysis published in JAMA demonstrated that bariatric surgery reduced mean AHI by 38.2 events per hour, with 75.8% of patients achieving significant clinical improvement in OSA severity. These data form the mechanistic rationale for using weight-loss pharmacotherapy as an OSA intervention: if enough adipose tissue is lost, upper airway anatomy improves, and AHI drops.

The question is whether pharmacologic weight loss with tirzepatide produces enough reduction in body weight to meaningfully change sleep apnea severity. The SURMOUNT-OSA program answered that question with randomized controlled data.

SURMOUNT-OSA Trial Results

The SURMOUNT-OSA program consisted of two parallel phase 3 randomized, double-blind, placebo-controlled trials published in the New England Journal of Medicine in June 2024 [4]. Trial 1 enrolled 114 participants with moderate-to-severe OSA (AHI ≥15 events/hour) who were unable or unwilling to use CPAP. Trial 2 enrolled 355 participants who were using CPAP at baseline. All participants had a BMI of 30 kg/m² or greater. The primary endpoint was change from baseline in AHI at 52 weeks.

Results were striking. In Trial 1, tirzepatide (titrated to a maximum of 15 mg weekly) reduced AHI by a mean of 25.3 events per hour compared with 5.3 events per hour in the placebo group, a treatment difference of 20.0 events per hour (95% CI, 12.6 to 27.4; P<0.001). In Trial 2, the tirzepatide group showed a mean AHI reduction of 29.3 events per hour versus 5.5 events per hour for placebo, a difference of 23.8 events per hour [4].

Weight loss mirrored what earlier SURMOUNT trials had shown. Participants on tirzepatide lost 18.1% of body weight in Trial 1 and 19.6% in Trial 2 at 52 weeks, compared with 1.3% and 2.3% in the respective placebo arms.

Secondary endpoints reinforced the primary finding. Oxygen desaturation index improved. Patient-reported sleepiness scores on the Epworth Sleepiness Scale dropped. Systolic blood pressure decreased by approximately 7 mmHg more than placebo. The proportion of participants whose OSA was reclassified from severe to moderate or mild was significantly higher in the tirzepatide groups.

These are strong efficacy signals, but several caveats apply. Both trials were sponsored by Eli Lilly. The 52-week duration does not establish durability of AHI improvement if treatment is discontinued. No head-to-head comparisons with CPAP, mandibular advancement devices, or bariatric surgery have been conducted. And the population studied had a mean BMI above 37 kg/m², so generalizability to patients with milder obesity or normal-weight positional OSA is uncertain.

Why Monitoring Matters for Off-Label Use

CPAP remains the gold-standard therapy for moderate-to-severe OSA because it mechanically splints the airway open. When a clinician adds or substitutes tirzepatide, the treatment effect depends entirely on progressive weight loss, and that weight loss takes months to reach a magnitude that changes airway caliber. During that interval, the patient's OSA may still be clinically significant.

According to the American Academy of Sleep Medicine's clinical practice guidelines, untreated moderate-to-severe OSA is associated with increased cardiovascular risk, excessive daytime sleepiness, motor vehicle accidents, and all-cause mortality [5]. A patient who discontinues CPAP in favor of tirzepatide without monitoring may spend 3-6 months with undertreated sleep apnea before enough weight is lost to reduce AHI below the treatment threshold.

Dr. Atul Malhotra, chief of pulmonary, critical care, and sleep medicine at UC San Diego and a principal investigator on the SURMOUNT-OSA trials, stated in the NEJM editorial discussion: "These results are encouraging, but they do not mean patients should stop CPAP. The role of tirzepatide is likely as an adjunct, reducing the pressure required and potentially allowing some patients to eventually discontinue positive airway pressure therapy under supervision" [4].

Monitoring also catches non-response early. Not every patient who loses weight will see proportional AHI improvement. Central sleep apnea, anatomic factors like retrognathia or tonsillar hypertrophy, and non-supine OSA patterns may persist regardless of adipose reduction. Without follow-up polysomnography or home sleep testing, non-response goes undetected.

A Structured Monitoring Protocol

No society has published a formal monitoring protocol for off-label tirzepatide use in OSA. The following framework draws on SURMOUNT-OSA study procedures, AASM guidelines for post-treatment reassessment, and clinical pharmacology of the drug [4][5][6].

Baseline (Week 0): A diagnostic polysomnography or home sleep apnea test (HSAT) within the prior 12 months establishes the reference AHI. Document the current CPAP pressure setting and mean hours of nightly use from device download data. Record body weight, BMI, neck circumference, blood pressure, fasting glucose, HbA1c, lipid panel, and an Epworth Sleepiness Scale score. Screen for contraindications to tirzepatide, including personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2, as noted in the FDA prescribing label [1].

Week 12 (3-Month Check): This visit coincides with the end of the standard titration phase, when most patients have reached their target dose. Repeat weight, blood pressure, and Epworth Sleepiness Scale. Review CPAP adherence data. If the patient has lost more than 5% of body weight, order an HSAT to check for AHI change and assess whether CPAP pressure reduction is needed. Gastrointestinal side effects (nausea, vomiting, diarrhea) are most common during dose titration; document severity and adjust dose if intolerable [1].

Week 26 (6-Month Check): Repeat HSAT or polysomnography regardless of weight trajectory. Compare AHI to baseline. If AHI has fallen below 5 events per hour, the patient may be a candidate for a supervised CPAP discontinuation trial with a follow-up sleep study at 4-6 weeks off CPAP to confirm sustained resolution. If AHI remains above 15 events per hour despite adequate weight loss, investigate alternative contributors (anatomic, central apnea component, positional factors). Recheck metabolic labs: fasting glucose, HbA1c, lipid panel, hepatic transaminases.

Week 52 (Annual Reassessment): Full reassessment including sleep study, metabolic panel, weight trend, and cardiovascular risk scoring. This is the time point at which SURMOUNT-OSA demonstrated its primary efficacy results. Discuss long-term continuation. Tirzepatide-associated weight loss reverses when the drug is stopped, as shown in the SURMOUNT-4 trial, where participants regained approximately two-thirds of lost weight within 52 weeks of discontinuation [7]. For patients whose OSA was the primary indication, stopping tirzepatide without an alternative weight-maintenance strategy will likely result in AHI rebound.

Adjusting CPAP Pressure During Treatment

As patients lose weight on tirzepatide, their CPAP pressure requirements often decrease. Over-pressurization causes aerophagia, mask leak, and central apneas, which reduce adherence. The AASM recommends auto-titrating CPAP (APAP) for patients undergoing active weight change, with a pressure range of 4 to 20 cmH2O and periodic download review [5].

A practical approach: switch the patient to APAP at baseline if they are on fixed-pressure CPAP. Review the 95th-percentile pressure from device data at each monitoring visit. If the 95th-percentile pressure has dropped by 3 cmH2O or more, narrow the pressure window. If residual AHI on APAP is consistently below 5, the device is doing its job and the patient can continue with confidence that their OSA is controlled during the weight-loss phase.

Patients who were previously non-adherent to CPAP may become willing to retry it at lower pressures after initial weight loss on tirzepatide. This is a practical advantage of combination therapy that the SURMOUNT-OSA Trial 2 design captured: the group already on CPAP saw AHI improvements that reflected both continued CPAP use and tirzepatide-driven weight reduction.

Safety Considerations Specific to OSA Patients

Tirzepatide's side-effect profile is dominated by gastrointestinal symptoms. In the SURMOUNT-1 trial (N=2,539), nausea occurred in 24-33% of tirzepatide-treated participants depending on dose, vomiting in 6-13%, and diarrhea in 12-23% [8]. These rates are consistent with the GLP-1 receptor agonist class. Most events were mild to moderate and concentrated during dose escalation.

For OSA patients specifically, two additional safety signals deserve attention. First, delayed gastric emptying caused by GLP-1 receptor agonism raises theoretical concern about aspiration risk during sedation. The American Society of Anesthesiologists issued guidance in 2023 recommending that GLP-1 receptor agonists be held before elective procedures requiring sedation [9]. OSA patients undergoing drug-induced sleep endoscopy (DISE) or surgical interventions should discuss medication timing with their anesthesiologist.

Second, rapid weight loss can reduce lean muscle mass alongside fat mass. The pharyngeal dilator muscles, particularly the genioglossus, contribute to airway patency during sleep. If lean mass loss disproportionately affects these muscles, OSA could theoretically worsen even as total body weight drops. This has not been observed in SURMOUNT-OSA data, but no trial has specifically measured pharyngeal muscle cross-sectional area with imaging during tirzepatide therapy. Resistance training during GLP-1 agonist therapy is supported by a 2024 analysis published in JAMA Network Open showing that structured exercise preserved lean mass during semaglutide-induced weight loss [10].

Who Is a Candidate for Off-Label Tirzepatide for OSA

Not every patient with sleep apnea should receive tirzepatide. The strongest clinical rationale exists for patients who meet all of the following criteria: BMI of 30 kg/m² or greater, moderate-to-severe OSA (AHI ≥15), and either CPAP intolerance or suboptimal adherence despite behavioral interventions. Patients who are already adherent to CPAP and achieving adequate AHI control may still benefit from tirzepatide for weight management, but the OSA indication in that scenario is secondary.

Patients with predominantly central sleep apnea, normal-weight OSA driven by craniofacial anatomy, or mild OSA (AHI 5-14) without obesity are unlikely to benefit from a weight-loss-first approach. In these groups, anatomic or neurologic drivers dominate over adipose-related airway narrowing.

Insurance coverage is another practical barrier. Zepbound carries a list price of approximately $1,060 per month without insurance. Coverage for the FDA-approved obesity indication is inconsistent across payers. Coverage for an off-label sleep apnea indication is even less likely unless the prescriber documents the weight-management indication as primary and the OSA benefit as secondary.

What the Data Cannot Tell Us Yet

The SURMOUNT-OSA program provides 52 weeks of efficacy and safety data. Several questions remain open. What happens to AHI if tirzepatide is continued beyond one year? The drug's weight-loss curve plateaus around 60-72 weeks based on SURMOUNT-1 data [8], so further AHI reduction beyond that point is unlikely, but stability of the achieved AHI reduction has not been confirmed beyond 52 weeks. Does tirzepatide reduce the cardiovascular consequences of OSA independently of weight loss? GIP and GLP-1 receptor agonism have direct cardiovascular effects, and the SELECT trial demonstrated that semaglutide reduced major cardiovascular events by 20% in patients with obesity [11]. Whether tirzepatide produces similar cardiovascular protection in the OSA subpopulation remains untested.

The FDA granted tirzepatide Breakthrough Therapy designation for moderate-to-severe OSA in late 2023, signaling that a formal indication may follow. Until that happens, prescribers and patients should treat this as what it is: a promising off-label application supported by moderate-quality randomized evidence that requires systematic monitoring to ensure safety and track response.

Clinicians prescribing tirzepatide off-label for OSA should order a follow-up sleep study no later than 26 weeks after treatment initiation and adjust or discontinue CPAP only when AHI on the follow-up study falls below 5 events per hour on two consecutive assessments [5].